Matrix Metalloproteinases in Coronary Artery Disease and Myocardial Infarction

Overview

Journal Basic Res Cardiol

Specialty Cardiology & Vascular Diseases

Date 2023 May 9

PMID 37160529

Authors

Hanna Brauninger

Saskia Kruger

Lucas Bacmeister

Alexander Nystrom

Kilian Eyerich

Dirk Westermann

Diana Lindner

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases (CVDs) remain the leading cause of death worldwide. Most cardiovascular deaths are caused by ischaemic heart diseases such as myocardial infarction (MI). Hereby atherosclerosis in the coronary arteries often precedes disease manifestation. Since tissue remodelling plays an important role in the development and progression of atherosclerosis as well as in outcome after MI, regulation of matrix metalloproteinases (MMPs) as the major ECM-degrading enzymes with diverse other functions is crucial. Here, we provide an overview of the expression profiles of MMPs in coronary artery and left ventricular tissue using publicly available data from whole tissue to single-cell resolution. To approach an association between MMP expression and the development and outcome of CVDs, we further review studies investigating polymorphisms in MMP genes since polymorphisms are known to have an impact on gene expression. This review therefore aims to shed light on the role of MMPs in atherosclerosis and MI by summarizing current knowledge from publically available datasets, human studies, and analyses of polymorphisms up to preclinical and clinical trials of pharmacological MMP inhibition.

Citing Articles

Successful emergency surgical intervention in acute non-ST-segment elevation myocardial infarction with rupture: A case report.

Li X, Wang Z, Yu H, Wang S World J Clin Cases. 2025; 13(4):100375.

PMID: 39917579 PMC: 11586794. DOI: 10.12998/wjcc.v13.i4.100375.

The role of the extracellular matrix in cardiac regeneration.

Wang X, Yu S, Xie L, Xiang M, Ma H Heliyon. 2025; 11(1):e41157.

PMID: 39834404 PMC: 11745795. DOI: 10.1016/j.heliyon.2024.e41157.

The interplay of senescence and MMPs in myocardial infarction: implications for cardiac aging and therapeutics.

Balaraman A, Altamimi A, Babu M, Goyal K, Padmapriya G, Bansal P Biogerontology. 2025; 26(1):46.

PMID: 39832057 DOI: 10.1007/s10522-025-10190-6.

Vaccination as a Promising Approach in Cardiovascular Risk Mitigation: Are We Ready to Embrace a Vaccine Strategy?.

Tsioulos G, Vallianou N, Skourtis A, Dalamaga M, Kotsi E, Kargioti S Biomolecules. 2025; 14(12.

PMID: 39766344 PMC: 11727084. DOI: 10.3390/biom14121637.

Short-Term Atorvastatin Therapy in Healthy Individuals Results in Unaltered Plasma MMP Levels and Disrupted MMP-7 Correlation with Blood Lipids and Blood Count-Derived Inflammatory Markers.

Manescu I, Manescu M, Barcutean L, Demian L, Dobreanu M J Clin Med. 2024; 13(16).

PMID: 39200884 PMC: 11355179. DOI: 10.3390/jcm13164743.

References

Panayiotou A, Griffin M, Tyllis T, Georgiou N, Bond D, Humphries S . Association of genotypes at the matrix metalloproteinase (MMP) loci with carotid IMT and presence of carotid and femoral atherosclerotic plaques. Vasc Med. 2013; 18(5):298-306. DOI: 10.1177/1358863X13502698. View

Deguchi J, Aikawa E, Libby P, Vachon J, Inada M, Krane S . Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation. 2005; 112(17):2708-15. DOI: 10.1161/CIRCULATIONAHA.105.562041. View

Di Gregoli K, Jenkins N, Salter R, White S, Newby A, Johnson J . MicroRNA-24 regulates macrophage behavior and retards atherosclerosis. Arterioscler Thromb Vasc Biol. 2014; 34(9):1990-2000. DOI: 10.1161/ATVBAHA.114.304088. View

Roczkowsky A, Chan B, Lee T, Mahmud Z, Hartley B, Julien O . Myocardial MMP-2 contributes to SERCA2a proteolysis during cardiac ischaemia-reperfusion injury. Cardiovasc Res. 2019; 116(5):1021-1031. DOI: 10.1093/cvr/cvz207. View

Mahdessian H, Perisic Matic L, Lengquist M, Gertow K, Sennblad B, Baldassarre D . Integrative studies implicate matrix metalloproteinase-12 as a culprit gene for large-artery atherosclerotic stroke. J Intern Med. 2017; 282(5):429-444. DOI: 10.1111/joim.12655. View

. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392(10159):1736-1788. PMC: 6227606. DOI: 10.1016/S0140-6736(18)32203-7. View

Wang X, Shi L . Association of matrix metalloproteinase-9 C1562T polymorphism and coronary artery disease: a meta-analysis. J Zhejiang Univ Sci B. 2014; 15(3):256-63. PMC: 3955912. DOI: 10.1631/jzus.B1300088. View

Vandenbroucke R, Libert C . Is there new hope for therapeutic matrix metalloproteinase inhibition?. Nat Rev Drug Discov. 2014; 13(12):904-27. DOI: 10.1038/nrd4390. View

Hudson M, Armstrong P, Ruzyllo W, Brum J, Cusmano L, Krzeski P . Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol. 2006; 48(1):15-20. DOI: 10.1016/j.jacc.2006.02.055. View

10.

Owolabi U, Amraotkar A, Coulter A, Singam N, Aladili B, Singh A . Change in matrix metalloproteinase 2, 3, and 9 levels at the time of and after acute atherothrombotic myocardial infarction. J Thromb Thrombolysis. 2019; 49(2):235-244. PMC: 9012982. DOI: 10.1007/s11239-019-02004-7. View

11.

Talman V, Ruskoaho H . Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016; 365(3):563-81. PMC: 5010608. DOI: 10.1007/s00441-016-2431-9. View

12.

Hughes B, Schulz R . Targeting MMP-2 to treat ischemic heart injury. Basic Res Cardiol. 2014; 109(4):424. DOI: 10.1007/s00395-014-0424-y. View

13.

Peeters W, Moll F, Vink A, van der Spek P, de Kleijn D, de Vries J . Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome. Eur Heart J. 2011; 32(18):2314-25. DOI: 10.1093/eurheartj/ehq517. View

14.

Galis Z, Sukhova G, Lark M, Libby P . Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94(6):2493-503. PMC: 330083. DOI: 10.1172/JCI117619. View

15.

Blankenberg S, Rupprecht H, Poirier O, Bickel C, Smieja M, Hafner G . Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003; 107(12):1579-85. DOI: 10.1161/01.CIR.0000058700.41738.12. View

16.

Beaudeux J, Giral P, Bruckert E, Bernard M, Foglietti M, Chapman M . Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis. 2003; 169(1):139-46. DOI: 10.1016/s0021-9150(03)00149-7. View

17.

Frangogiannis N . The Extracellular Matrix in Ischemic and Nonischemic Heart Failure. Circ Res. 2019; 125(1):117-146. PMC: 6588179. DOI: 10.1161/CIRCRESAHA.119.311148. View

18.

Martin T, Penney D, Smith J, Groenning B, Dargie H, Hillis G . Matrix metalloproteinase-1 promoter polymorphisms and changes in left ventricular volume following acute myocardial infarction. Am J Cardiol. 2004; 94(8):1044-6. DOI: 10.1016/j.amjcard.2004.06.064. View

19.

Zhao M, Ye S, Su J, Garg V . Cardiomyocyte Proliferation and Maturation: Two Sides of the Same Coin for Heart Regeneration. Front Cell Dev Biol. 2020; 8:594226. PMC: 7593613. DOI: 10.3389/fcell.2020.594226. View

20.

de Castro Bras L, Cates C, DeLeon-Pennell K, Ma Y, Padmanabhan Iyer R, Halade G . Citrate synthase is a novel in vivo matrix metalloproteinase-9 substrate that regulates mitochondrial function in the postmyocardial infarction left ventricle. Antioxid Redox Signal. 2014; 21(14):1974-85. PMC: 4208600. DOI: 10.1089/ars.2013.5411. View